The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.

Replimune gets a second chance, while Sarclisa could go subcutaneous.

Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.

Progression-free and overall survival data from Companion-002 are due this quarter.

A biliary tract cancer trial hits on response rate, but survival data will be key.

First-in-human trial initiations feature Interius, Umoja and Vironexis.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.